Identification of Coinfections by Viral and Bacterial Pathogens in COVID-19 Hospitalized Patients in Peru: Molecular Diagnosis and Clinical Characteristics

Identification of Coinfections by Viral and Bacterial Pathogens in COVID-19 Hospitalized Patients in Peru: Molecular Diagnosis and Clinical Characteristics

The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Giancarlo Pérez-Lazo, Wilmer Silva-Caso, Juana del Valle-Mendoza, Adriana Morales-Moreno, José Ballena-López, Fernando Soto-Febres, Johanna Martins-Luna, Hugo Carrillo-Ng, Luís J. del Valle, Sungmin Kym, Miguel Angel Aguilar-Luis, Issac Peña-Tuesta, Carmen Tinco-Valdez, Luis Ricardo Illescas
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
coinfections
COVID-19
antibiotics
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/6001f795b10149c4a9eecb445d48cdd3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were <i>Mycoplasma pneumoniae</i> (28.1%), <i>Chlamydia pneumoniae</i> (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), <i>Mycoplasma pneumoniae</i>/Adenovirus (0.7%), <i>Chlamydia pneumoniae</i>/Adenovirus (0.7%), RSV-B/<i>Chlamydia pneumoniae</i> (0.3%) and <i>Mycoplasma pneumoniae</i>/<i>Chlamydia pneumoniae</i>/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for <i>Mycoplasma pneumoniae</i> and <i>Chlamydia pneumoniae</i>.

Ejemplares similares